Details
Category: Volume 06 Issue 01 January 2018
Hits: 1761

Title: A Study of Clinical Profile and Biochemical Parameters in Multiple Myeloma

Authors: Dr Hanock Unni Samuel, Dr Abdul Majeed .K

 DOI:  https://dx.doi.org/10.18535/jmscr/v6i1.133

Abstract

This study is to assess the clinical and biochemical profile of patients with multiple myeloma who presented to a tertiary health centre in northern kerala. This is a prospective observational study which started in January 2015 and was completed in December 2015. All patients more than 12years of age, diagnosed to have multiple myeloma as per the IMWG 2014 diagnostic criteria and who gave an informed consent were analysed in the study. A total of 65 patients were included who were evaluated using detailed clinical history, thorough clinical examination and relevant laboratory investigations including bone marrow study. The quality of life of the patients were assessed by the EORTC QLQ-C30 scoring system. The clinical profile of patients encountered in our setting is was studied, the average age of presentation of patients being 61.4±7.6 yrs and 95.38% belonged to poor socioeconomic status, male to female ratio of patients with multiple myeloma was  0.97:1.The quality of life of the patients was 0.59.The most common associations of multiple myeloma were anemia Hb<10mg/dl (69.2%), elevated ESR ≥100mm/hr (73.8%), elevated serum creatinine >2mg/dl (43.1%), low albumin levels <3.5g/dl (70.8%). The most common type of immunoglobulin seen in multiple myeloma was IgG (75.4%) and bone marrow plasma cells between 20-29% was seen in a majority (46.2%) patients.

Keywords: Multiple myeloma; Clinicalprofile; Quality of life.

References

  1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011. CA: a cancer journal for clinicians. 2011 Jul 1;61(4):212-36.
  2. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008 Mar 1;111(5):2521-6.
  3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA: a cancer journal for clinicians. 2010 Sep 1;60(5):277-300.
  4. Bergsagel DE, Wong O, Bergsagel PL, Alexanian R, Anderson K, Kyle RA et al. Benzene and multiple myeloma: Appraisal of the scientific evidence. Blood. 1999 Aug 15; 94(4):1174-82.
  5. Bayrd ED, Heck FJ. Multiple myeloma: a review of eighty-three proved cases. Journal of the American Medical Association. 1947 Jan 18;133(3):147-57.
  6. Wuilleme-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia. 2005 Jul 1;19(7):1248-52.
  7. Berenson James R. Biology and management of Multiple myeloma humana Press. 2004. ISBN 0-89603-706-1;
  8. Pruzanski W, Ogryzlo MA. Abnormal proteinuria in malignant diseases. Advances in clinical chemistry. 1970 Dec 31;13:335-82.
  9. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009 Feb 1;23(2):215-24.
  10. Kühnemund A, Liebisch P, Bauchmüller K, ZurHausen A, Veelken H, Wäsch R et al. ‘Light-chain escape-multiple myeloma’—an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. Journal of cancer research and clinical oncology. 2009 Mar 1;135(3):477-84.
  11. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, DispenzieriA et al. Review of 1027 patients with newly diagnosed multiple myeloma. In Mayo Clinic Proceedings 2003 Jan 31 (Vol. 78, No. 1, pp. 21-33). Elsevier.
  12. Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010 Jan 1; 24(1):22-32.
  13. Kaufman JL, Nooka A, Vrana M, Gleason C, Heffner LT, Lonial S. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma. Cancer. 2010 Jul 1;116(13):3143-51.
  14. Durie BG, Stock-Novack D, Salmon SE, Finley P, Beckord J, Crowley J et al. Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study [see comments]. Blood. 1990 Feb 15;75(4):823-30.
  15. Chang WJ, Kang ES, Lee ST, Kim SH, Kim DW, Kim SJ et al. Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation. Actahaematologica. 2014 Apr 8;132(2):226-32.
  16. Kaur P, Shah BS, Baja P. Multiple myeloma: a clinical and pathological profile. Gulf J Oncolog. 2014 Jul;1(16):14-20.
  17. Morgan GJ, Child JA, Gregory WM, Szubert AJ, Cocks K, Bell SE et al Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. The lancet oncology. 2011 Aug 31;12(8):743-52.
  18. Dmoszynska A, Walter-Croneck A, Hus I, Grzasko N, Manko J, Jedrzejczak WW et al. The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma—A report by the Polish Myeloma Study Group. Leukemia research. 2010 Oct 31;34(10):1330-5.
  19. Gupta P, Kochupillai V, Singh S, Berry M, Kumar L, Sundaram KR. A twelve year study of multiple myeloma at the all india institute of medical sciences, new delhi, india. Indian Journal of Medical and Paediatric Oncology. 1995 Jun 1; 16(2):108.
  20. Kim K, Lee JH, Kim JS, Min CK, Yoon SS, Shimizu K et al. Clinical profiles of multiple myeloma in Asia—An Asian Myeloma Network study. American journal of hematology. 2014 Jul 1;89(7):751-6.

Corresponding Author

Dr Hanock Unni Samuel

TC 32-1079, Mannil House, Ggra, Kanjirampara, Trivandrum-695030, Kerala,India

Phone No: 9400864173, 04712364173

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.